MARKET

IMVT

IMVT

Immunovant Inc
NASDAQ
33.26
-0.75
-2.19%
Opening 14:37 09/25 EDT
OPEN
34.00
PREV CLOSE
34.00
HIGH
34.22
LOW
33.19
VOLUME
735.44K
TURNOVER
--
52 WEEK HIGH
45.42
52 WEEK LOW
14.58
MARKET CAP
6.87B
P/E (TTM)
-11.8333
1D
5D
1M
3M
1Y
5Y
1D
Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)
Barchart · 5h ago
How Investors May Respond To Immunovant (IMVT) Skin Lupus Drug Halt
Simply Wall St · 23h ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Scholar Rock Holding (SRRK) and Immunovant (IMVT)
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Immunovant (IMVT) and Ionis Pharmaceuticals (IONS)
TipRanks · 2d ago
Immunovant Down Over 7%, On Pace for Largest Percent Decrease Since July 2025 -- Data Talk
Dow Jones · 2d ago
Immunovant Stock Slides After Biotech Scraps Autoimmune Drug Program
Barron‘s · 2d ago
Analysts Are Bullish on These Healthcare Stocks: Immunovant (IMVT), Oruka Therapeutics (ORKA)
TipRanks · 2d ago
Wainwright maintains confidence in Immunovant’s pipeline despite CLE setback
TipRanks · 2d ago
More
About IMVT
Immunovant, Inc. is a clinical-stage immunology company enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The Company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).

Webull offers Immunovant Inc stock information, including NASDAQ: IMVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMVT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMVT stock methods without spending real money on the virtual paper trading platform.